SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
VALHALLA, N.Y. and SOUTH PLAINFIELD, N.J., Aug. 08, 2017 -- Today, New York Medical College and Touro College of Pharmacy announced the wider availability of their joint Continuing Medical Education (CME) course, Principles of Genomics and Introduction to Personalized Medicine. The course which premiered live on March 21st, has been archived and is available through webinar with the goal of providing the medical community more exposure to pharmacogenomics (PGx). The CME course was made possible by an educational grant from molecular diagnostic company, Admera Health (www.admerahealth.com).
The course introduces the principles of PGx; specifically, how genetic variability can lead to different drug responses. The course then provides specific clinical case studies in the therapeutic areas of cardiology, oncology, psychiatry, and pain management. Other topics covered are Electronic Health Records and Reimbursement.
“As a leader in healthcare education, the CME program in pharmacogenomics is a natural fit with our institution’s commitment to life-long learning. Through both our curriculum, as well as our extensive research program in pharmacogenomics, Touro provides its students with significant exposure and practical experience in this cutting-edge area. We thank Admera Health for their support towards this initiative,” stated Dr. Zvi Loewy, Professor and Chair Pharmaceutical and Biomedical Sciences, Touro College of Pharmacy and Adjunct Professor, New York Medical College.
“This provides us an avenue to help educate the medical community on the importance of pharmacogenomics. As PGx testing becomes the standard of care, it has the potential to significantly reduce the number of Adverse Drug Events and drive down medical costs,” stated Guanghui Hu, PhD, President and CEO of Admera. Hu continued, “Given our position as the market leader in pharmacogenomics testing, this sponsorship opportunity was perfect fit for us.”
Admera Health offers PGxOne™ Plus testing, a PGx test assaying 50 genes and providing clinical recommendations for over 300 drugs.
About the Touro College and University System
Touro is a system of non-profit institutions of higher and professional education. Touro College was chartered in 1970 primarily to enrich the Jewish heritage, and to serve the larger American and global community. Approximately 18,000 students are currently enrolled in its various schools and divisions. Touro College has 30 campuses and locations in New York, California, Nevada, Berlin, Jerusalem and Moscow. New York Medical College; Touro University California and its Nevada branch campus; Touro University Worldwide and its Touro College Los Angeles division; as well as Hebrew Theological College in Skokie, Ill. are separately accredited institutions within the Touro College and University System. For further information on Touro College, please go to: www.touro.edu/news
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is Admera’s mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. Admera health is committed to improving the health and well-being of the global community through the direct delivery of personalized, medically actionable results.
Touro College of Pharmacy Contact Zvi G. Loewy, Ph.D. Professor and Chair Pharmaceutical and Biomedical Sciences 646-981-4718 [email protected] Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
